Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (22)
- Safety monitoring and information (13)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
114 result(s) found, displaying 1 to 10
-
PagePharmaceutical company Novo Nordisk will gradually discontinue some of its earlier generation insulin products between late 2024 and late 2026. We recognise the vital role of insulin for people with diabetes in Australia and will work to minimise the impact of these discontinuations by providing early advice that includes alternative options.
-
PageInformation about the shortage and the Serious Scarcity Substitution Instrument
-
PageInformation about the shortage and the Serious Scarcity Substitution Instrument
-
PageKey information and updates about the shortage of Creon (pancreatic extract) capsules.
-
PageKey information and updates about the shortage of metformin immediate-release tablets.
-
Medicine shortage alertsPharmaceutical companies Novo Nordisk and Eli Lilly are discontinuing some of their insulin products.
-
Medicine shortage alertsSupply constraints will apply to Creon 25,000 unit and 35,000 unit capsules until 30 June 2026.
-
PageFind out about the shortage of Pegasys (peginterferon alfa-2a) injection.
-
GuidanceThis guidance is to assist entities and individuals planning to export medicines (including prescription, over-the-counter (OTC) and complementary medicines) either for commercial supply, or for non-commercial purposes (for example, for a family member or friend).
-
PageInformation for sponsors and applicants preparing applications and requests involving steps in the manufacture of medicines regulated as prescription medicines.